REGENXBIO Prices Public Offering at $100 Million

By Philip Seaworth • Monday, July 20 13:02 • Permanent Link

REGENXBIO said it priced a public offering that will bring in about $100 million in gross proceeds before fees and expenses.

The company is selling 10,003,889 shares of common stock at $9.00 apiece and 1,111,111 pre-funded warrants at $8.9999 each. At those prices, the stock sale accounts for about $90.0 million of the total and the warrants about $10.0 million.

REGENXBIO also gave underwriters a 30-day option to buy up to 1,667,250 additional shares. If that option is exercised in full, the company would sell roughly 16.7% more shares than the base offering of 10,003,889.

The offering is expected to close on July 20, 2026.

This is the latest financing move for the biotech company, which is advancing a pipeline that includes RGX-202 for Duchenne muscular dystrophy, ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-121 for MPS II and RGX-111 for MPS I. Today the company's shares have moved 5.06% to a price of $10.39. For the full picture, make sure to review REGENXBIO's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.